Apolipoprotein E (apoE) is a multifunctional plasma glyco-
Introduction
Atherosclerosis is the primary cause of death in industrialised countries and is rapidly becoming the leading cause of death and disability in the rest of the world. 1, 2 In the United Kingdom, 38% of premature deaths in men and 30% of premature deaths in women are due to cardiovascular disease. 3 Atherosclerosis is caused by the inflammatory deposition of lipoprotein-derived cholesterol into the artery wall resulting in the development of fatty streaks that go on to form atherosclerotic plaques, leading to local occlusion of the arteries and consequently cardiovascular disease. 4 A major component within lipoprotein metabolic pathways that plays a role in preventing development of atherosclerotic lesions is apolipoprotein E (apoE). ApoE is a major glycoprotein constituent of lipoprotein particles involved in the transport of excess cholesterol from the peripheral tissues to the liver for excretion, a process known as reverse cholesterol transport. [5] [6] [7] ApoE is the ligand for the low-density lipoprotein receptor (LDL-R) and the LDL-R-related protein (LRP) expressed by the liver. Interaction of apoE with cell-surface heparan sulphate proteoglycans (HSPG) is also the first stage in clearance of remnant particles by the liver and is part of the LRP lipoprotein clearance pathway. 8 Through these interactions, apoE mediates the hepatic clearance of cholesterol-rich dietary chylomicron remnants, very low-density lipoproteins (VLDLs), intermediate density lipoproteins (IDLs) and a subclass of high-density lipoproteins (HDLs) from the circulation. 6, 9 Also apoE plays a part in cholesterol efflux from cells in atherosclerotic lesions via ␥LpE, an immature HDL particle in which apoE is the sole protein component. [10] [11] [12] There are three major variant isoforms of apoE, designated apoE2, apoE3 and apoE4 (encoded by polymorphic alleles, ⑀2, ⑀3 and ⑀4), of which apoE3 is the most common functional isoform. 6, 13 Genetic deficiency in apoE and also the presence of apo⑀2 and apo⑀4 genes in the population are associated with predisposition to atherosclerosis and Alzheimer's disease, respectively. 13, 14 In particular homozygosity for apo⑀2 is associated with type III hyperlipoproteinaemia, which is characterised by elevated levels of the chylomicron remnants, VLDL and IDL, with concomitant increases in cholesterol and triglyceride levels and with consequent predisposition to premature atherosclerosis. 15 
Gene Therapy
The apoE -/-transgenic mouse has been used extensively as an animal model for atherosclerosis as it develops severe hypercholesterolaemia and atherosclerotic lesions similar to those found in humans. 16, 17 ApoE is normally expressed predominantly by hepatocytes and macrophage cells of haematopoietic lineage, and transplantation of normal bone marrow cells into apoE -/-mice results in increased lipoprotein clearance, reversal of hypercholesterolaemia, and protection against development of atherosclerosis. 18, 19 Liver-directed somatic gene transfer with recombinant adenovirus vectors (rAds) containing the apoE3 cDNA has also been shown to result in transient normalisation of lipoprotein and cholesterol plasma profiles and inhibition of atherosclerotic lesion development. 20, 21 ApoE2 is less efficient at correcting the hyperlipidaemic phenotype compared with apoE3, due to reduced efficiency in mediating lipoprotein plasma clearance and liver uptake, but nevertheless has been shown to exhibit residual anti-atherogenic activity and retardation of atherosclerotic lesion development in apoE -/-mice, following liver-and muscle-directed gene transfer. 22, 23 A major limitation of studies utilising rAd vectors to mediate apoE gene transfer has been the induction of adverse host immune and inflammatory responses, 24, 25 which lead to only transient transduction and to rapid target cell elimination. For studies showing quantitative regression of atherosclerotic plaques, recourse to immunodeficient athymic apoE -/-mice was required.
26
Recombinant adeno-associated viruses (rAAVs) are attractive candidate vectors for gene therapy as they are defective and non-pathogenic, 27 can transduce both dividing and non-dividing cells, and are devoid of viral structural genes which diminishes the risk of adverse host immune responses. 28, 29 In particular, the use of skeletal muscle as a heterologous site for gene delivery with rAAV vectors has gained increasing importance as a platform for the secretion of therapeutic transgene products into the circulation. Thus, skeletal muscle is well vascularised, accessible and actively secretory. 30 Several studies have shown that after intramuscular injection of rAAV vectors, there was a gradual increase in transgene expression over several weeks that reached a plateau of sustained expression. 29, [31] [32] [33] [34] [35] [36] In a study by Xiao et al 31 LacZ expression was maintained for more than 1.5 years with no evidence of immune elimination of transduced myofibres or response against the reporter transgene product.
In the present study we have constructed and tested rAAV-based vectors containing human apoE transgenes for heterologous muscle-based expression in apoE -/-mice. ApoE mRNA was present in transduced muscles, and despite low plasma levels of recombinant products, circulating antibodies to human apoE and rAAV were induced. In the case of rAAV encoding human apoE3, but not apoE2, a single intramuscular administration resulted in significant (approximately 30%) reduction in atherosclerotic plaque density in the aorta of treated animals. The results indicate that heterologous, musclebased and rAAV-mediated expression of human apoE3 is protective against atherosclerotic progression in this welldefined genetic model, even in the presence of a humoral immune response directed against the transgene product and virus capsid proteins. 
Results

Construction and in vitro testing of rAAV vectors expressing human apoE transgenes
Recombinant rAAV vectors containing a transgene expression cassette consisting of the full cytomegalovirus (CMV) immediate-early enhancer/promoter driving expression of the human apo-⑀2 or apo-⑀3 cDNAs were used to assess the ability of the rAAV vectors to infect and engineer cells to express the transgenes (Figure 1 ). HeLa and 293-T cells were infected with rAAV/apoE2 ( Figure 2 ) or rAAV/apoE3 (data not shown) at high MOIs and 3 days later culture supernatants were harvested. Western blot analysis demonstrated that human apoE had accumulated in the culture supernatants even in the absence of the rAd helper virus Ad-␤Gal ( Figure 2 ).
In vivo transduction of skeletal muscle with rAAV/apoE2 and rAAV/apoE3 vectors in apoE -/-mice ApoE -/-mice at 6-8 weeks of age were injected with 2.5 × 10 10 virus particles of either rAAV/apoE2 or rAAV/apoE3 vectors into both tibialis anterior (TA) muscles. Tail vein bleeds were taken at 2, 4, 6, 10 and 14 weeks, and plasma samples evaluated for the presence of either human apoE2 or apoE3 proteins by ELISA and Western blot analysis. At all time-points the levels of transgene products in the circulation of the treated animals were undetectable and thus fell below the sensi- tivity limits of these methods (ie Ͻ10 ng/ml). Muscle tissues from the site of rAAV injection were collected at 14 weeks and total RNA extracted. RT-PCR analysis of muscle RNAs, using human apoE-specific primers common to both the ⑀2 and ⑀3 isotypes, demonstrated the presence of an appropriate 227-bp amplification product in all treated samples, but not in control muscles ( Figure  3a ). In addition, restriction fragment length polymorphism isotyping confirmed that the RT-PCR products were derived from the respective apoE transcripts, as HhaI digestion produced restriction fragments of the expected size for the apoE2 and apoE3 genotypes (Figure 3b ).
Humoral immune response against human apoE transgene products and rAAV virions
Plasma samples from groups of rAAV-treated mice at the various time-points, were pooled and screened for antibodies against transgene product and rAAV capsid proteins by Western blot analysis against partially purified recombinant human apoE and rAAV vector, respectively. ApoE antibodies were detected from 4 to 6 weeks after rAAV administration and levels increased throughout the course of the experiment (Figure 4a ). For the detection of anti-AAV antibodies plasmas were screened against Western blots of intact rAAV/apoE virus stock. Here AAV capsid antibodies were clearly present again, from 2 weeks after injection, increasing marginally up to 10 to 14 weeks when the animals were killed (Figure 4b ). Antibodies to human apoE or AAV capsid proteins were not detected in plasma samples from the mock-injected control animals. 
Plasma cholesterol levels in mice transduced with rAAV/apoE vectors
Plasma samples from individual mice were evaluated for total cholesterol levels at 2, 4, 6, 10 and 14 weeks after intramuscular injection of rAAV/apoE vectors. At 2 weeks, plasma samples from animals treated with rAAV/apoE2 or rAAV/apoE3 demonstrated mean total cholesterol levels of 346 mg/dl and 435 mg/dl, respectively, with the control group giving a value of 440 mg/dl ( Figure 5a ; the normal range for wild-type mice is 80-150 mg/dl 37, 38 ). Statistical analysis established that the reduction in plasma cholesterol in the rAAV/apoE2 treated group was significant at the 2-week time-point only (P = 0.005). This initial disparity between the rAAV/apoE2-treated and the control group was only transient and by 6 weeks the difference in cholesterol levels between these two groups was insignificant. No significant effect of rAAV/apoE3 transduction on plasma cholesterol levels was observed. Upon analysis of the lipoprotein particle distribution at 2 and 10 weeks after rAAV/apoE vector administrations, no appreciable changes were observed (Figure 5b ).
Analysis of atherosclerotic lesion density in aortas of rAAV/apoE transduced mice
To investigate the effect of human apoE gene transfer upon atherosclerotic lesion development, apoE -/-mice were injected with rAAV vectors and killed at 14 weeks. Aortas were dissected, opened along their entire length, fixed intact and treated with Oil-Red-O which specifically stains lipid-laden atherosclerotic lesions (Figure 6a ). Those mice treated with the rAAV/apoE3 vector demonstrated reduced levels of Oil-Red-O stained atherosclerotic and fatty streak lesions compared with the control group (Figure 6a and b) . Aortas of rAAV/apoE3-treated animals had a total lesion coverage area of 16.4 ± 1.6%, and the control group gave a mean value of 23.0 ± 2.2% (mean ± s.e.m.; Figure 6b ). Therefore the rAAV/apoE3-treated group of animals demonstrated a significant reduction in aortic lesion density of 29% (P = 0.033) compared with control apoE -/-mice. In the case of animals injected with rAAV/apoE2, the mean aortic lesion area Gene Therapy was also reduced (20.8 ± 1.28%), but this was not significant compared with the control group (P = 0.39).
Figure 5 Evaluation of total plasma cholesterol levels and lipoprotein distribution in apoE -/-mice after intramuscular injection of rAAV/apoE vectors. (a) Total plasma cholesterol levels were determined for individual animals at 2, 4, 6 and 10 weeks after injection. A statistically significant lowering of cholesterol was observed at 2 weeks in the rAAV
Discussion
ApoE -/-mice are characterised by having severe hypercholesterolaemia with plasma cholesterol levels of between 400 to 800 mg/dl, developing premature atherosclerosis on a normal chow diet, and are a relevant model of human atherosclerotic disease. 17, 37, 38 The restoration of normal cholesterolaemic levels and protection against atherosclerosis has been achieved in apoE -/-animal models by the gene transfer of human apoE, using retroviral, adenoviral and plasmid expression vectors. 22, 23, 26, [39] [40] [41] As a platform for secretion of therapeutic proteins into the circulation, muscle has been used extensively in rAAVmediated gene transfer yielding sustained transgene expression in the absence of immune clearance of transduced cells. 29, [31] [32] [33] [34] [35] We have examined the feasibility of targeting muscle as a platform for the secretion of anti-atherogenic proteins by the transfection of mouse myoblast cultures with rAAV-based plasmid vectors containing apoA1 and LCAT cDNAs. 42 A significant improvement in secretion of apoA1 and LCAT and retention of vector sequences by transfected cells was observed using the rAAV-based vectors compared with conventional plasmid expression vectors. We also demonstrated that cultured mouse C2C12 cells transfected with a plasmid expression vector containing the CMV promoter driving expression of the human apoE2 or apoE3 cDNAs, can express and secrete human apoE. 23 The secreted proteins became incorporated into spherical lipoprotein particles similar to those involved in cholesterol efflux, [10] [11] [12] thereby providing evidence for the functional activity of the expressed proteins. In addition, intramuscular injection of an apoE expression plasmid in apoE -/-mice, resulted in secretion of apoE and retardation of aortic atherosclerotic lesions. 23 In support of these findings, Rinaldi et al 41 also performed intramuscular injections of a plasmid expressing the apoE cDNA, resulting in reduction of serum cholesterol, improved hepatic clearance of VLDL, IDL and LDL cholesterol and an increase in HDL cholesterol.
Our present studies aim to combine the efficient rAAVmediated transduction of muscle with the antiatherogenic properties of apoE. Intramuscular injection of apoE -/-mice with the rAAV/apoE vectors resulted in apoE expression below ELISA and Western blot detection limits. However, indirect evidence for apoE expression was demonstrated by the generation of circulating apoE antibodies and detection of apoE transgene mRNAs in muscle tissues 4-6 weeks and 14 weeks, respectively, after transduction. Previously, we have shown that following intramuscular injection of plasmids containing the apoE transgene cassettes employed in this study, apoE2 and apoE3 transgene products were effectively secreted into the circulation. 23 Furthermore, apoE -/-mice subjected to muscle transduction with rAAV/apoE3 vectors exhibited significant reduction in aortic atherosclerotic lesion density even in the absence of altered plasma cholesterol levels. Herzog et al 34, 43 have previously detected high-titre antibodies to human factor IX (hFIX) after muscle transduction with rAAV/hFIX vectors in mice and dogs, but other studies have demonstrated a lack of an immune response against rAAV transgene products. [31] [32] [33] 44 In one instance, intramuscular injection of an rAAV vector expressing ␤-galactosidase resulted in an immune response after 4 weeks, followed by immune tolerance and long-term expression of the foreign protein. 35 According to Joos et al, 44 rAAV-mediated intramuscular gene transfer evades the immune system by the inability of the vector to transduce antigen-presenting cells. Thus it is likely that only when the transgene product is secreted or membrane-associated may a humoral immune response develop, and the reported variability in the immune responses may reflect differences in immunogenicity of foreign proteins and the immunology of animal model/strains. In a recent study, apoE -/-nude mice were treated with a first generation adenovirus containing human apoE cDNA and complete regression of atherosclerosis was demonstrated 6 months after injection. 26 As these animals were immune deficient, no immune response was mounted against the adenovirus vector and recognition of human apoE as a neoantigen was minimal which resulted in prolonged transgene expression.
Previous studies have demonstrated that low levels of apoE in apoE -/-mice can inhibit atherosclerosis without reducing cholesterol levels. Thorngate et al 45 generated
Figure 6 Reduction in aortic atherosclerotic lesions in apoE -/-mice treated with rAAV/apoE2 and rAAV/apoE3. Animals were killed 14 weeks after rAAV vector administration and the aortas removed, pinned out en face on to cork beds and stained with Oil-Red-O. (a) Representative aortas from the rAAV/apoE3 treated and untreated animals. The red-stained areas denote the accumulation of neutral lipids in the vessel wall. Scale bar = 1 mm. (b) Mean percent aortic lesion areas of the untreated and rAAV treated animals. * Comparison of the mean of the rAAV/apoE3-treated group against the mean of the control group using a two-tailed unpaired t test.
transgenic apoE -/-mice expressing apoE (approximately 1 g/ml plasma: Ͻ2% of wild-type levels) from the adrenal glands, and although hypercholesterolaemia was not corrected, significant protection against atherosclerosis occurred. Inhibition of atherosclerotic lesion development has also been achieved by retrovirus-mediated ex vivo transduction and re-implantation of apoE -/-bone marrow stem cells yielding plasma apoE3 levels of approximately 1% of normal without correction of hypercholesterolaemia. 39 In this case, reduction in atherosclerosis was reported only in young mice (5-10 weeks) and not in older animals (13 to 26 weeks). Our results support this finding as the mice evaluated in the present study were treated at 6-8 weeks of age and therefore, low plasma apoE levels appeared to be effective at inhibiting lesion development in the early stages of atherogenesis in the absence of lowering plasma cholesterol. In this respect, local effects of apoE in situ, at the atherosclerotic lesion site may be an important parameter in controlling atherosclerotic lesion progression, secondary to the lowering of plasma cholesterol levels. Notably, deposition of recombinant apoE3 within atherosclerotic lesions has been demonstrated following rAd-mediated liver transduction, 22 and associated with macrophages following bone marrow transplantation. 39 A defining stage in the development of atherosclerotic lesions that precedes the attachment of monocytes to the vessel wall, is the accumulation of remnant lipoproteins on the intimal extracellular matrix which occurs as early as 3 weeks of age in apoE -/-mice. 46 The presence of low levels of apoE in the circulation may prevent the recruitment of the remnant lipoproteins to the vessel wall and therefore protect against the development of atherosclerosis. 45 This may explain how low levels of human apoE in the circulation of apoE -/-mice can protect against early lesion development. Other anti-atherogenic properties of apoE include the inhibition of platelet aggregation, 47 lymphocyte activation and proliferation, 48 
inhibition of
Gene Therapy smooth muscle cell proliferation, 49 suppression of vascular cell adhesion molecule-1 (VCAM-1) that is involved in the recruitment of monocytes to the site of lesion development, 50 and anti-oxidant activity that prevents the formation of oxidised LDL, which is a major factor in foam cell formation.
14,51 The significant reduction in lesion development of animals treated with rAAV/apoE3 compared with those treated with rAAV/apoE2, may reflect the association of apoE2 with type III hyperlipoproteinaemia, where individuals homozygous for apoE2 are prone to developing premature atherosclerosis. ApoE plays a major part in cholesterol efflux from cells in atherosclerotic lesions via ␥LpE, an immature HDL particle of which apoE is the sole protein component. [10] [11] [12] The efficiency of this process is isoform-dependent with apoE3 being more efficient in forming ␥LpE particles, reflected by the much enhanced ability of ⑀3/⑀3 plasma samples to mobilise cell-derived cholesterol compared with ⑀2/⑀2 subjects. 11 A direct comparison of apoE2, apoE3 and apoE4 isoforms by adenoviral gene transfer into apoE -/-mice, demonstrated the impaired ability of apoE2 to clear VLDL, IDL and remnant lipoproteins from the circulation compared with apoE3 and apoE4, 22, 40 due to reduced affinity for the LDL-R and LRP. 6, 52, 53 In addition to a humoral immune response against apoE2 and apoE3, antibodies directed against the virus capsid proteins VP1 and VP2 were present 4-6 weeks after vector administration. Over the course of the analysis, anti-AAV antibody titres rose marginally, compared with a more pronounced increase of antibodies against apoE. This may reflect the ongoing expression of apoE2 and apoE3 transgene products from muscle sites, compared with only the exogenous source of virus antigen. While the presence of neutralising antibodies to AAV would likely preclude efficient readministration of rAAV vectors, transient immuno-blockade at the time of rAAV vector administration can result in successful rAAV vector readministration. 54 This study has demonstrated that expression of low levels of human apoE3 in apoE -/-mice by intramuscular injection of rAAV vectors leads to a significant reduction in atherosclerotic aortic lesion development, and confirms previous studies. 23, 39, 41, 45 The low circulating levels of apoE in the present study indicate that significant improvements are necessary in order to achieve complete protection against atherosclerosis using muscle-based rAAV-mediated gene transfer. In this respect, the current rAAV vectors are based upon AAV serotype-2, and recent studies indicate muscle expression following rAAV transduction can be increased by up to 100-fold using vectors based upon AAV serotypes 1 and 5. 55 In addition, targeting slow-twitch muscle fibres, as opposed to fast-twitch muscle fibres (which predominate in the TA muscle sites used here) may also improve rAAVmediated transduction due to increased levels of cell surface HSPG, a primary receptor for AAV. 56 
Materials and methods rAAV vector construction
The rAAV plasmid vectors were constructed using pNTC3-CMV␤, 23, 42 which contains the 5'-and 3'-ITRs between which is a CMV promoter/LacZ expression cassette. The LacZ gene was deleted from pNTC3-CMV␤ by NotI and EcoRV digestion, and replaced with the human apoE2 and apoE3 cDNAs excised from their respective pUC-based vectors, 57 using HincII/SmaI digestion then blunt-ended, producing the rAAV plasmid vectors pAAV/apoE2 and pAAV/apoE3. rAAV production and purification For the production of rAAV vectors, pAAV/apoE2 or pAAV/apoE3 were co-transfected with the helper plasmid pDG into 293-T cells, 58, 59 at a molar ratio of 1:1. The pDG plasmid contains the rep and cap genes and adenovirus helper functions required for rAAV production. Cell lysates were prepared 2 days after the transfection and rAAV particles purified by iodixanol stepped gradient centrifugation as previously described. 60 Final virus stocks were stored in PBS-MK (phosphate buffered saline, 5 mm MgCl 2 , 12.5 mm KCl) and were titred by determining the rAAV vector genome copy number using DNA dot-blot hybridization. 61 From 10 15-cm dishes of transfected 293-T cells, between 5 × 10 11 and 2 × 10 12 rAAV particles were isolated and purified on a routine basis.
Culture and rAAV/apoE infection of HeLa and 293-T cells
HeLa and 293-T cells were routinely passaged to subconfluency in DMEM containing 10% fetal bovine serum (Life Technologies, Paisley, UK), 2 mm l-glutamine, 100 U/ml penicillin, 100 g/ml streptomycin and 250 ng/ml amphotericin B at 37°C and 8% CO 2 . Hela and 293-T cells were seeded in six-well plates at 3 × 10 5 and 8 × 10 5 cells per well, respectively. The following day HeLa and 293-T cells were infected with the rAAV vectors at an MOI of 100 000 and 30 400, respectively. Cell culture supernatants were replaced with 700 l of infection mix containing 3.8 × 10 10 rAAV/apoE2 virus particles in PBS/MgCl 2 /CaCl 2 (phosphate buffered saline containing 49 mm MgCl 2 and 68 mm CaCl 2 ). As indicated, a first generation adenovirus containing the LacZ gene (Ad␤Gal) was used as helper adenovirus at an MOI of 50. After 3 h at 37°C/8% CO 2 the infection mixes were replaced with fresh culture medium and the culture media was harvested 3 days later for analysis of secreted human apoE proteins.
rAAV vector administration in vivo
Female apoE -/-mice provided by GlaxoSmithkline (Stevenage, UK), were generated by inactivation of the mouse apoE locus through homologous recombination as previously described. 16 The animals were maintained on a normal chow diet and blood samples were taken after a 4 h fast from the tail vein. The rAAV vector stocks were diluted to 6.25 × 10 11 viral particles/ml using PBS-MK and 40 l (2.5 × 10 10 virus particles) of either rAAV/apoE2 or rAAV/apoE3 were injected into both TA muscles of mice anaesthetised by intra-peritoneal administration of a 25% solution of hypnorm and hypnovel (3 l per gram body weight). Control animals were injected with PBS-MK only. Tail vein bleeds were carried out where approximately 50 l of blood was anti-coagulated with sodium citrate. Plasma samples were stored at Ϫ80°C.
Detection of human apoE in culture supernatants and plasma from treated apoE -/-mice by Western blotting analysis
Culture supernatant from transduced cells or plasma samples, were denatured by the addition of SDS-PAGE sample buffer containing 2.5% (v/v) ␤-mercapto-ethanol and heating at 100°C for 5 min. Samples were then subjected to 4-12% SDS-NuPAGE gradient electrophoresis (Invitrogen/Novex, Groningen, The Netherlands), and resolved proteins transferred to an ECL-nitrocellulose membrane (Amersham Pharmacia Biotech, Little Chalfont, UK). Nitrocellulose blots were incubated with goat anti-human apoE antibody (1:3000 dilution; Biogenesis Ltd, Poole, UK) followed by an anti-goat-HRP secondary antibody (1:3000 dilution; Sigma, Poole, UK). Blots were developed using the ECL detection system (Amersham Pharmacia Biotech).
Enzyme-linked immunosorbent assay (ELISA) for quantification of human apoE
Human apoE2 or apoE3 in mouse plasma was detected by a two-antibody sandwich ELISA. Polyclonal goat antihuman apoE antibodies were used both for capture (DiaSorin Inc, Stillwater, MN, USA) and after biotinylation using a commercial kit (Amersham Pharmacia Biotech), for detection (Biogenesis Ltd, Poole, Dorset). Purified human apoE (Technoclone Ltd, Dorking, Surrey) was used as a standard. Standard and mouse plasma samples were diluted in assay buffer, 150 mm NaCl, pH 7.4 containing 0.5 % (w/v) bovine serum albumin, 0.05 % (w/v) gamma-globulin, 0.01 % (v/v) Tween-40 and 50 mm Tris; the detection limit was 10 ng/ml.
RT-PCR analysis
Total RNA was isolated from TA muscle that had been frozen in liquid nitrogen then stored at Ϫ80°C immediately after removal from the animals. Each muscle was thawed out in 0.5 ml of RNAlater (Ambion, Abingdon, UK) and sliced into small pieces, followed by isolation of total RNA with Trizol Reagent (Life Technologies), according to the manufacturer's instructions. DNase treated RNA (1 g) was reverse transcribed with Superscript II RNase H -Reverse Transcriptase (Life Technologies) and an oligo (dT) [12] [13] [14] [15] [16] [17] [18] primer at 42°C, following the manufacturer's instructions. The derived cDNA (1 l from a 20 l reaction) was used to amplify a 227 bp product using a primer set specific for the human apoE sequence. Each reaction contained 25 pmol of each primer (sense: 5'-TCCAAGGAGCTGCAGGCGG CGCA-3'; antisense: 5'-ACAGAATTCGCCCCGGCCTGG TACACTGCCA-3'), 200 m of each deoxynucleotide triphosphate, 10% DMSO, 0.5 l Pfu Turbo polymerase and 10× reaction buffer for Pfu Turbo polymerase (Stratagene, Amsterdam, The Netherlands) in a final volume of 50 l. The reaction conditions were 94°C for 5 min followed by the addition of the polymerase; then 30 cycles of 94°C for 1 min, 62°C for 1 min and 72°C for 1 min followed by a final extension time of 72°C for 10 min. To confirm the quality of RNA preparations, a mouse ␤-actin primer set (Stratagene) was used to amplify a 514 bp product from 2 l of cDNA. Each reaction contained 50 pmol of each primer, 200 m of each deoxynucleotide triphosphate, 1.5 mm MgCl 2 and 10× reaction buffer (Life Technologies) for Taq DNA polymerase. The reaction conditions were 94°C for 45 s followed by the addition of the polymerase; then thermal cycling was carried out for 30 cycles (45 s 94°C; 45 s 60°C; 90 s 72°C), followed by a final extension time of 72°C for 10 min. The PCR products were visualised by electrophoresis on a 1.8% agarose gel. Restriction enzyme apoE isoform genotyping was performed to demonstrate that the amplified products were specifically derived from rAAV/apoE2 and rAAV/apoE3. 62 Briefly, gel-purified PCR products were subjected to digestion with the restriction enzyme HhaI (New England Biolabs, Hitchin, UK) followed by 20% PAGE and then stained with ethidium bromide to visualise the restriction fragments.
Detection of anti-ApoE and anti-AAV antibodies by Western blotting analysis
For the detection of anti-human apoE antibodies in mouse plasma, human apoE3 was partially purified from CHO cells stably expressing the protein (CHO-apoE3). 63 CHO-apoE3 cells were cultured in CD-CHO medium (Life Technologies), which requires no addition of serum and contains 20 times less protein than conventional growth media. Human apoE3 was partially purified from the culture supernatant by concentration using a Vivaspin 30 kDa filter (Vivascience Ltd, Binbrook, UK), followed by dialysis against PBS. Human apoE3 protein (1 g) was denatured by the addition of SDS-PAGE sample buffer containing 2.5% (v/v) ␤-mercaptoethanol and heating to 100°C for 5 min. Then the protein was loaded into a preparative well of a 4-12% SDS-NuPAGE (Invitrogen/Novex) and subjected to electrophoresis. For the detection of antibodies against the virus vector, 2.25 × 10 11 viral particles of rAAV/apoE3 was used in place of the partially purified human apoE3. The electrophoresed proteins were transferred to a Hybond-PVDF membrane (Amersham Pharmacia Biotech) and placed in a Mini-PROTEAN II multiscreen apparatus (BioRad, Hemel Hempstead, UK). Equal volumes of mouse plasma from each animal within each treatment group were pooled and 2.5 l was diluted in 600 l of incubation buffer (TBST containing 2.5% milk powder, 0.05% Tween-20 and 0.2% 2-chloroacetamide) and this was used to screen for Gene Therapy antibodies against human apoE. The same primary incubation buffer was used for the detection of anti-AAV capsid proteins. As positive controls for the detection of antiapoE and anti-AAV antibodies, a mouse monoclonal antihuman apoE3 antibody, 64 and an anti-AAV antibody that recognises VP1, VP2 and VP3 capsid proteins (Clone B1, Progen Immunodiagnostika, Heidelberg, Germany) were used, respectively. A goat anti-mouse-HRP (Jackson Laboratories, Bar Harbor, ME, USA) was used as a secondary antibody, followed by detection using ECL Western blotting detection reagents (Amersham Pharmacia Biotech).
Determination of plasma cholesterol levels
Plasmas from tail-vein bleeds were diluted 1/10 in PBS and 10 l was used to estimate total cholesterol levels by the infinity cholesterol reagent assay system (Sigma), as described by the manufacturer. Briefly, the assay was performed in microtitre 96-well plates and 90 l of infinity cholesterol reagent per sample was used followed by an incubation at 37°C for 5 min and then measuring the absorbance at 510 nm.
Plasma lipoprotein distribution analysis
Lipoprotein profiles of pooled plasma (2 l) was performed by electrophoresis on precast alkaline buffered (pH 8.8) agarose gels (YSI, Farnborough, UK) followed by staining with a lipid-specific Sudan black stain according to the manufacturer's instructions. The concentrations of the Sudan black-stained lipoprotein fractions were determined by scanning densitometry using an imaging densitometer model GS-670 with Molecular Analyst Version 1.4 software (BioRad).
Dissection and examination of aorta for atherosclerotic lesions
Following the death of the animals, the hearts and thoracic aortas were taken and any adventitial fat was dissected away before cutting the aortas longitudinally and then pinning them out en face on to cork beds. The dissected aortas were stained with Oil-Red-O stain (Sigma) modified from previously described methods. 22, 23 Briefly, the aortas were fixed in PBS/4% formaldehyde for 3 days, washed in PBS followed by staining with 1.8% OilRed-O in 60% isopropanol for 15 min at room temperature, then destained in 60% isopropanol for 5 min. The stained aortas were transferred to PBS for storage at 4°C. Images of the aortas were captured with a Nikon digital camera and analysis of aortic lesion area from the aortic root down to the diaphragm, including the aortic arch, was achieved using the image analysis software Sigma Scan Pro5.
